These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24419084)

  • 1. LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors.
    de la Roche M; Ibrahim AE; Mieszczanek J; Bienz M
    Cancer Res; 2014 Mar; 74(5):1495-505. PubMed ID: 24419084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
    PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.
    de la Roche M; Worm J; Bienz M
    BMC Cancer; 2008 Jul; 8():199. PubMed ID: 18627596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling.
    Adachi S; Jigami T; Yasui T; Nakano T; Ohwada S; Omori Y; Sugano S; Ohkawara B; Shibuya H; Nakamura T; Akiyama T
    Cancer Res; 2004 Dec; 64(23):8496-501. PubMed ID: 15574752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin.
    Lo YH; Noah TK; Chen MS; Zou W; Borras E; Vilar E; Shroyer NF
    Gastroenterology; 2017 Jul; 153(1):205-218.e8. PubMed ID: 28390865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells.
    Bao R; Christova T; Song S; Angers S; Yan X; Attisano L
    PLoS One; 2012; 7(11):e48670. PubMed ID: 23144924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity.
    Pedersen NM; Thorvaldsen TE; Schultz SW; Wenzel EM; Stenmark H
    PLoS One; 2016; 11(8):e0160507. PubMed ID: 27482906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tankyrase inhibition aggravates kidney injury in the absence of CD2AP.
    Kuusela S; Wang H; Wasik AA; Suleiman H; Lehtonen S
    Cell Death Dis; 2016 Jul; 7(7):e2302. PubMed ID: 27441654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
    Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA
    PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of zinc-finger BED domain-containing 3 (Zbed3) as a novel Axin-interacting protein that activates Wnt/beta-catenin signaling.
    Chen T; Li M; Ding Y; Zhang LS; Xi Y; Pan WJ; Tao DL; Wang JY; Li L
    J Biol Chem; 2009 Mar; 284(11):6683-9. PubMed ID: 19141611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.
    Huang SM; Mishina YM; Liu S; Cheung A; Stegmeier F; Michaud GA; Charlat O; Wiellette E; Zhang Y; Wiessner S; Hild M; Shi X; Wilson CJ; Mickanin C; Myer V; Fazal A; Tomlinson R; Serluca F; Shao W; Cheng H; Shultz M; Rau C; Schirle M; Schlegl J; Ghidelli S; Fawell S; Lu C; Curtis D; Kirschner MW; Lengauer C; Finan PM; Tallarico JA; Bouwmeester T; Porter JA; Bauer A; Cong F
    Nature; 2009 Oct; 461(7264):614-20. PubMed ID: 19759537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
    de la Roche M; Rutherford TJ; Gupta D; Veprintsev DB; Saxty B; Freund SM; Bienz M
    Nat Commun; 2012 Feb; 3():680. PubMed ID: 22353711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
    Croy HE; Fuller CN; Giannotti J; Robinson P; Foley AVA; Yamulla RJ; Cosgriff S; Greaves BD; von Kleeck RA; An HH; Powers CM; Tran JK; Tocker AM; Jacob KD; Davis BK; Roberts DM
    J Biol Chem; 2016 Jun; 291(24):12747-12760. PubMed ID: 27068743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells.
    Luo F; Li J; Liu J; Liu K
    Cancer Gene Ther; 2022 Nov; 29(11):1707-1719. PubMed ID: 35750753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
    Jang MK; Mashima T; Seimiya H
    Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.